Compare GSK plc (GSK) vs Synchrony Financial (SYF) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs Synchrony Financial — how do they compare? GSK plc trades at $52.79 (market cap $101.34B), while Synchrony Financial trades at $74.15 (market cap $24.90B). The key difference: GSK plc is far larger — about 4.1× Synchrony Financial's market cap, and GSK plc pays the higher dividend (3.49%). Which is the better fit depends on your goals.
| GSK | SYF | |
|---|---|---|
Market Cap | $101.34B | $24.90B |
Sector | Health | Financials |
52-Week High | $61.18 | $88.47 |
52-Week Low | $36.20 | $63.78 |
Enterprise Value | $121.95B | — |
Dividend Yield | 3.49% | 1.62% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK's stock trades at $51.25, down 1.99% on the day, with a bearish technical signal from moving averages. Fundamentally, the company shows strong profitability with a 17.78% net margin and 36.42% ROE, supported by a consistent earnings beat history. Recent positive clinical trial results for Jemperli in rectal cancer and FDA approval for Utebzi highlight pipeline progress. Valuation appears reasonable with a P/E of 13.71 and EV/EBITDA of 9.16.
The outlook balances a solid core business and promising oncology pipeline against a mixed analyst consensus and near-term cash flow pressures. Key opportunities lie in execution of new drug launches and the upcoming CEO strategy update, while risks include clinical trial setbacks, competitive pressures, and integration of potential acquisitions like Nuvalent.
Synchrony Financial (SYF) trades at $74.11, up 0.58% with strong fundamentals including a 7.66 P/E ratio and 24.06% net income margin. The stock shows bearish technical signals despite three consecutive earnings beats, with Q2 2026 results expected on July 21. Recent corporate developments include executive leadership changes and new digital partnerships, while analyst consensus remains strongly bullish with a $86.38 price target.
SYF presents value opportunity with attractive valuation metrics and consistent earnings performance, though technical indicators suggest near-term pressure. Key risks include credit quality sensitivity to economic conditions and competitive pressures in consumer lending. The 16% upside to consensus target and zero sell ratings support the bullish analyst sentiment despite current technical weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About Synchrony Financial
Synchrony Financial is a premier consumer financial services company and the largest provider of private-label credit cards in the United States. Spun off from GE Capital in 2014, it operates through a unique B2B2C model, embedding its financing products within the ecosystems of major partners like Amazon, Lowe’s, and PayPal. Synchrony leverages deep data analytics and a diverse multi-platform strategy—spanning retail, health, and auto—to drive customer loyalty and provide specialized credit solutions at the point of sale.
Read more on SYF →
